Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than alzheimer's disease

Journal of Alzheimer's Disease

Volumn 30, Issue 1, 2012, Pages 53-61

  Hughes, Timothy M ^a   Kuller, Lewis H ^a   Lopez, Oscar L ^b   Becker, James T ^b   Evans, Rhobert W ^a   Sutton Tyrrell, Kim ^a   Rosano, Caterina ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

24S hydroxycholesterol; cerebrovascular disease; dementia and Alzheimer's disease; oxysterols

Indexed keywords

24S HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; OXYSTEROL; UNCLASSIFIED DRUG;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; BRAIN INFARCTION; BRAIN RADIOGRAPHY; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SEX DIFFERENCE; WHITE MATTER LESION;

EID: 84861501372     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111460     Document Type: Article

References (34)

1. Kuller LH (2007) Statins and dementia. Curr Atheroscler Rep 9, 154-161. (Pubitemid 47376986)
2. McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev 2, CD003160.
3. Reiss A (2005) Cholesterol and apolipoprotein E in Alzheimer's disease. Am J Alzheimers Dis Other Dement 20, 91-96. (Pubitemid 40547349)
4. Bjorkhem I (2006) Crossing the barrier: Oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 260, 493-508. (Pubitemid 44772369)
5. Leoni V (2009) Oxysterols as markers of neurological disease-a review. Scan J Clin Lab Invest 69, 22-25.
6. Solomon A, Leoni V, Kivipelto M, Besga A, Oksengard A, Julin P, Svensson L, Wahlund L, Andreasen N, Winblad B, Soininen H, Björkhem I (2009) Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairments but not with Alzheimer's disease. Neurosci Lett 462, 89-93.
7. Lutjohann D, Papasotiropoulus A, Bjorkhem I, Locatelli S, Bagli M, Oehring R, Schlegel U, Jessen F, Rao M, von Bergmann K, Heun R (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) isincreasedinAlzheimer and vascular dementia patients. J Lipid Res 41, 195-198. (Pubitemid 30117859)
8. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund L, Diczfalusy U, Hillert J, Björkhem I (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42, 186-191. (Pubitemid 38401447)
9. Bretillon L, Siden A, Wahlund L, Lütjohann D, Minthon L, Crisby M, Hillert J, Groth C, Diczfalusy U, Björkhem I (2000) Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 293, 87-90.
10. Papassotiropoulus A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Rao M, Maier W, Björkhem I, von Bergmann K, Heun R (2000) Plasma 24S-hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuro Report 26, 1959-1962.
11. Teunissen C, De, Vente J, Steinbusch H, De Bruijn C (2003) Serum cholesterol, precursors and metabolites and cognitive performanceinanaging population. Neurobiol Aging 24, 147-155. (Pubitemid 35454151)
12. van den Kommer T, Dik M, Comijs H, Fassbender K, Lütjohann D, Jonker C (2009) Total cholesterol and oxys-terols: Early markers for cognitive decline in elderly? Neurobiol Aging 30, 534-545.
13. Koschack J, Lütjohann D, Schmidt-Samoa C, Irle E (2009) Serum 24S-hydroxycholesterol and hippocampal size in middle-aged normal individuals. Neurobiol Aging 30, 898-902.
14. Thelen K, Falkai R, Bayer T, Lütjohann D (2006) Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci Lett 403, 15-19. (Pubitemid 43963235)
15. Heverin M, Bagdanovic N, Lütjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Björkhem I (2004) Changes in the level of cerebral and extracerebral sterols in the brain of patient with alzheimer's disease. J Lipid Res 45, 186-192.
16. Cushman M, Cornell E, Howard P, Bovill E, Tracy R (1995) Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41, 264-270.
17. Dzeletovic S, Breuer O, Lund E, Diczfalusy U (1995) Determination of cholesterols oxidation products in human plasma by isotope dilution-mass spectroscopy. Anal Biochem 225, 73-80.
18. Bland J, Altman D (1987) Statistical methods for assessing agreement between measurement. Biochim Clin 11, 399-404.
19. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the Concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499-502.
20. Lopez OL, Kuller LH, Becker JT, Dulberg C, Sweet RA, Gach HM, DeKosky ST (2007) Incidence of dementia in mild cognitive impairment in the Cardiovascular health study cognition study. Arch Neurol 64, 416-420. (Pubitemid 46425698)
21. Kuller L, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, Burke G, Tracy R, Bhadelia R (1998) Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 29, 388-398. (Pubitemid 28086681)
22. Bartzokis G (2011) Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 32, 1341-1371.
23. Kuller L, Longstreth W, Arnold A, Bernick C, Bryan R, Beauchamp N, Group CHSCR (2004) White matter hyper-intensity on cranial magnetic resonance imaging: A predictor of stroke. Stroke 35, 1821-1825. (Pubitemid 38971858)
24. Holdenrieder S, Lutjohann D (2004) Does brain specific 24S-hydroxycholesteroll in plasma indicate the disruption of blood-brain barrier inpatients with ischemic stroke? Neurosci Lett 368, 201-204. (Pubitemid 39194872)
25. Snipes G, Suter U (1997) Cholesterol and myelin. Subcell Biochem 28, 173-204.
26. Fassbender K, Stoick M, Bertsch T, Ragoschke A, Kuehl S, Walter S, Walter J, Brechtel K, Muehlhauser F, Von Bergmann K, Lütjohann D (2002) Effects of statins on cerebral cholesterol metabolism and secretionofAlzheimer amyloid peptide. Neurology 59, 1699-1258.
27. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lan-nfelt L, Winblad B, Russell DW, Björkhem I (2001) On the turnover of brain cholesterol in patients with Alzheimer's dis-ease. Abnormal induction ofthe cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314, 45-48. (Pubitemid 33043802)
28. Karrenbauer V, Leoni V, Lim E, Giovannoni G, Ingle G, Sastre-Garriga J, Thompson A, Rashid W, Davies G, Miller D, Björkhem I, Masterman T (2006) Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin Neurol Neurosurg 108, 456-460. (Pubitemid 43744509)
29. Kolsch H, Heun R, Kerksiek A, Bergmann K, Maier W, Lütjohann D (2004) Altered levels of plasma 24S-and 27-hdroxycholesterol in demented patients. Neurosci Lett 368, 303-308. (Pubitemid 39214973)
30. Burkard I, von Eckardstein A, Waeber G, Vollenweider P, Rentsch KM (2007) Lipoprotein distribution and biological variation of 24S-and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis 194, 71-78. (Pubitemid 47464309)
31. Schroepfer GJ (2000) Oxysterols: Modulators of cholesterol metabolism and other processes. Physiol Rev 80, 361-554.
32. Lund EG, Guileyardo JM, Russell DW (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96, 7238-7243. (Pubitemid 29299645)
33. Russell D, Halford R, Ramirez R, Kotti T (2009) Cholesterol 24-hydroxylase: An enzyme of cholesterol turnover in the brain. Annu Rev Biochem 78, 1017-1040.
34. Price J, Klunk W, Lopresti B, Lu X, Hoge J, Ziolko S, Holt D, Meltzer C, DeKosky S, Mathis C (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25, 1528-1547. (Pubitemid 41541962)